A Multicenter Observational Study of Incretin-based Drugs and Heart Failure | Zendy

Kristian B. Filion | Zendy; Laurent Azoulay | Zendy; Robert W. Platt | Zendy; Matthew Dahl | Zendy; Colin R. Dormuth | Zendy; Kristin K. Clemens | Zendy; Nianping Hu | Zendy; J. Michael Paterson | Zendy; Laura E. Targownik | Zendy; Tanvir Chowdhury Turin | Zendy; Jacob A. Udell | Zendy; Pierre Ernst | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Multicenter Observational Study of Incretin-based Drugs and Heart Failure

Author(s) -

Kristian B. Filion,

Laurent Azoulay,

Robert W. Platt,

Matthew Dahl,

Colin R. Dormuth,

Kristin K. Clemens,

Nianping Hu,

J. Michael Paterson,

Laura E. Targownik,

Tanvir Chowdhury Turin,

Jacob A. Udell,

Pierre Ernst

Publication year - 2016

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1506115

Subject(s) - medicine , hazard ratio , heart failure , incretin , diabetes mellitus , confidence interval , cohort study , cohort , type 2 diabetes , dipeptidyl peptidase 4 , endocrinology

There is concern that antidiabetic incretin-based drugs, including dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) analogues, can increase the risk of heart failure. Ongoing clinical trials may not have large enough samples to effectively address this issue.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research